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Abstract
Background: To assess the ability of the Chromatest in investigating diabetic maculopathy.
Method: Patients with Type 2 diabetes and no concurrent ocular pathology or previous laser
photocoagulation were recruited. Visual acuities were assessed followed by colour contrast
sensitivity testing of each eye using Chromatest. Dilated fundoscopy with slit lamp biomicroscopy
with 78 D lens was then performed to confirm the stage of diabetic retinopathy according to the
Early Treatment Diabetic Retinopathy Study.
Results: 150 eyes in 150 patients were recruited into this study. 35 eyes with no previous laser
photocoagulation were shown to have clinically significant macular oedema (CSMO) and 115 eyes
with untreated non-proliferative diabetic retinopathy (NPDR) on fundus biomicroscopy. Statistical
significant difference was found between CSMO and NPDR eyes for protan colour contrast
threshold (p = 0.01). Statistical significance was found between CSMO and NPDR eyes for tritan
colour contrast threshold (p = 0.0002). Sensitivity and specificity for screening of CSMO using pass-
fail criterion for age matched TCCT results achieved 71% (95% confidence interval: 53–85%) and
70% (95% confidence interval: 60–78%), respectively. However, threshold levels were derived using
the same data set for both training and testing the effectiveness since this was the first study of
NPDR using the Chromatest
Conclusion: The ChromaTest is a simple, cheap, easy to use, and quick test for colour contrast
sensitivity. This study did not achieve results to justify use of the Chromatest for screening, but it
reinforced the changes seen in tritan colour vision in diabetic retinopathy.
Background
The debilitating nature of untreated diabetic retinopathy
promotes the need for cost-effective screening methods.
Various studies have shown that cost effective screening
can reduce blind registration due to diabetes [1-3].
Although seven field 30 degree stereo colour fundus pho-
tographs are the gold standard for diabetic screening, both
remain relatively expensive and difficult to obtain [4,5].
In the UK, the National Screening Program for Diabetic
Retinopathy utilises non-stereo digital photography as
this meets the Diabetes UK standards for sensitivity and
specificity.
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Non-stereo fundus imaging is easier to obtain but has lim-
itations in establishing macular oedema [6]. There is evi-
dence that tritan colour vision is diminished in patients
with diabetic maculopathy, but testing with the FM100
hue and Farnsworth-Lanthony D-15 test are labour inten-
sive and time consuming [7]. Colour vision testing with a
computer graphics system is an effective alternative [8].
This study assesses the ability of an automated, digital col-
our contrast sensitivity program in investigating diabetic
maculopathy.
Methods
Patients from either the Diabetic Eye Screening Service or
patients returning for their follow-up appointment in the
Medical Retina Service were recruited for this study. Inclu-
sion criteria included Type 2 diabetic patients with
untreated non-proliferative diabetic retinopathy (NPDR)
and untreated clinically significant macular oedema
(CSMO). Exclusion criteria included Type 1 diabetes, pro-
liferative diabetic retinopathy, previous laser photocoagu-
lation, and concurrent ocular pathology including
infection, trauma, amblyopia, glaucoma, and/or vascular
occlusion.
Medical history including duration of diabetes, hyperten-
sion, renal disease, recent HbA1c, and smoking were
recorded. Concurrent eye disease and previous treatment
were also recorded. Examination of best corrected logMar
visual acuities (BCVA) was followed by colour contrast
sensitivity testing of each eye by occluding the fellow eye
and using the diabetic module of ChromaTest, a software
program analyzing the age-corrected tritan (TCCT) and
protan color contrast thresholds (PCCT). A brief explana-
tion of what the patient is expected to see and their
expected response was made prior to the test. The right eye
was tested first followed by the left.
For the Chromatest, the subject is seated at a fixed distance
from the monitor so the alphabetical letter displayed on
the computer screen subtends a constant angle on the ret-
ina. The letter size creates an image that tests the central
6.5 degrees of the retina. The letters are displayed on a
background of equiluminance. The operator has no influ-
ence on the contrast of the test letter given. The computer
finds the endpoint of the test by a Modified Binary Search
method; if response is correct, on the next presentation
the colour difference between letter and background is
halved. If response is incorrect, the colour -contrast is dou-
bled. Incorrect responses prolong the test, but do not
influence the final threshold. This method of determining
thresholds leads to finite steps which reach a plateau at
the colour contrast sensitivity threshold. The reproduci-
bility of this measurement is 1%, which is the sensitivity
of the test. The Chromatest has been further described in
various articles [8-10]. Control data was obtained from
unpublished data collected by G.B. Arden from diabetic
patients without any diabetic retinopathy prior to this
study (Table 1). Test and training sets are both from the
group studied in this report.
Dilated fundoscopy with slit lamp biomicroscopy and 78
D lens was performed by a specialist registrar (RW) to con-
firm the grading of CSMO according to the Early Treat-
ment Diabetic Retinopathy Study extension of the
modified Airlie House classification [11]. CSMO is
defined as any retinal thickening within 500 microns of
the centre of the fovea; hard, yellow exudates within 500
microns of the centre of the fovea with adjacent retinal
thickening; or at least 1 disc area of retinal thickening, any
part of which is within 1 disc are of the centre of the fovea.
Each age group (eg. 30–49 years old, 50–69, 70–89) sep-
arated by 2 decades was assigned pass-fail criterion for
TCCT as previous data suggests age related change in
threshold for tritan colour. Since this is the first study of
NPDR using the Chromatest, threshold levels were
derived using the same data set for both training and test-
Table 1: Colour Contrast Sensitivity in Patients with Diabetes 
and No Clinical Retinopathy (N = 30)
Age Tritan Protan
37 12.4 2.5
44 9.4 3.1
48 4.2 4.2
48 4.1 2.9
48 4.2 2.4
51 11.3 5.9
51 4.2 2.5
51 5.9 4.7
54 6.9 6.6
54 4.1 4.8
54 7.9 3.7
57 6.8 2.5
59 8.6 2.5
59 9.4 2.4
60 15.7 2.6
60 6.2 5.4
61 15.7 11.6
62 7.1 2.7
62 8.6 11.4
64 7.9 3.7
67 9.4 5.1
67 13.6 5.4
68 17.3 5.4
68 11.7 5.71
69 6.8 6.8
69 13.9 4.7
70 17.3 4.7
70 12.4 5
71 6.7 3.8
72 21.7 5.4
Control: Age, TCCT, PCCTBMC Ophthalmology 2008, 8:15 http://www.biomedcentral.com/1471-2415/8/15
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ing the effectiveness. Pass-fail criterion for each age group
was chosen piecewise and sensitivity/specificity calcula-
tions were made according to these arbitrarily assigned
levels.
Sensitivity, specificity, confidence intervals, and χ2 test were
calculated by web-based statistical calculator made availa-
ble by Professor Lowry at Vassar College, New York http://
faculty.vassar.edu/lowry/VassarStats.html. Wilcoxon Rank
Sum Test for non-parametric statistical analysis was per-
formed using web software http://www.fon.hum.uva.nl/
Service/Statistics/Wilcoxon_Test.html.
Results
150 eyes of 150 patients were included in this study. Of
the 150 eyes, 115 eyes had untreated NPDR (Table 2) and
35 eyes had untreated CSMO (Table 3). Median age was
60 years. Median duration of diabetes was 16.0 years.
Median LogMar BCVA for NPDR patients was 0.20 and for
CSMO patients was 0.20. Interquartile range for VA NPDR
and CSMO was 0.20 and 0.30, respectively. Median PCCT
for NPDR was 3.9% and for CSMO patients was 5.6%.
Wilcoxon Rank Sum Test analysis revealed statistical sig-
nificant difference between CSMO and NPDR eyes for
PCCT (p = 0.01). When compared to controls with sample
size N = 30 (Table 1), PCCT for NPDR had no statistical
significance (p = 0.15) whereas PCCT for CSMO was sig-
nificant (p = 0.002). Median TCCT for NPDR was 15.4%
and for CSME patients was 29.6%. Statistical significance
was found between CSMO and NPDR eyes for TCCT (p =
0.0002). Both were also statistically significant when com-
pared to controls (p < 0.001)
The piecewise pass/fail criterion for TCCT for each age
group was as follows: 11.0 (30–49 year old); 23.0 (50–69
year old); 32.0 (70–89 year old). Sensitivity and specifi-
city for screening of CSMO using the above pass-fail crite-
rion for age matched TCCT results achieved 71% (95%
confidence interval: 53–85%) and 70% (95% confidence
interval: 60–78%), respectively (Table 4).
When repeating the analysis in Table 4 for only subjects
with logMar BCVA > = 0.1, sensitivity to detect CSMO
improves to 75% (CI: 47–91%) and specificity to 85%
(CI: 67–89%) p = 0.0002. Similarly, when repeating the
analysis in Table 4 for only subjects with CSMO with cen-
tral macular thickening, sensitivity to detect CSMO
improves to 83.3% (CI: 58–96%) p < 0.0001.
Discussion
Cost effective screening for chronic and debilitating disor-
ders such as diabetic retinopathy is not only important to
the well being of the patient, but these healthy adults con-
tribute to the economy of a nation. With the rise in type 2
Table 2: Colour Contrast Sensitivity in Patients with NPDR (N = 
115)
Age Log Mar VA Tritan Protan
31 0 13.6 3.4
32 0 5.2 3.2
32 0 6.7 2
32 0.2 15.4 3.2
41 0 16.1 15.4
41 0 6.1 2.1
41 0 6.2 2.1
41 0 6 1.7
41 0 8.4 3.9
42 0 11.4 3
44 0.2 9.6 4.8
44 0.2 13.3 8.1
45 0.2 16.1 4.2
45 0.2 22.1 5.5
45 0.4 19.9 5.8
48 0 5.6 2.9
48 0.5 20.6 3.8
48 0.6 29.5 5
49 0 7.4 3.4
49 0 6.3 2.2
49 0 8.4 3.9
49 0 8.4 2.6
49 0 9.4 3.1
49 0 9.9 3.4
49 0 10.3 2.9
49 0 30.5 6.1
49 0 34.5 4
49 0.1 33.6 6
49 0.7 9.2 2.6
49 0.7 12.2 3.6
51 0 13.6 4.4
51 0.1 18 5.8
51 0.2 19.1 7
52 0 10.8 2.6
52 0.2 82.4 9.3
54 0 9 3.1
54 0 22.1 4.6
54 0.2 23.6 4.3
55 0 14.4 3.1
55 0 20.2 5.4
55 0.2 18.4 3.5
55 0.2 17.6 2.1
55 0.3 19.6 4.4
55 0.3 85.9 7.7
55 0.4 22.1 7.7
56 0 8.1 2.7
56 0 11.1 2.5
56 0.1 6.6 2.6
57 0 10.3 3.6
57 0.1 6.7 2.9
57 0.1 7.2 2.1
57 0.2 14.9 2.9
58 0.1 13.9 3.8
58 0.2 11 3.3
58 0.2 21.4 2.8
58 0.2 38 3.8
59 0.2 6.8 2.1
59 0.2 6.3 1.4BMC Ophthalmology 2008, 8:15 http://www.biomedcentral.com/1471-2415/8/15
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diabetes in obese adolescents due to dietary and lifestyle
changes, the need for an optimal method of screening for
sight threatening diabetic retinopathy becomes a critical
essential [12].
Abnormal protan and especially tritan colour vision is
associated with diabetic retinopathy [13]. Blue-yellow
defect has also been described in both diabetic retinopa-
thy and glaucoma [14]. In contrast to the optotype used
for testing macular function, the Chromatest has a sepa-
rate glaucoma module for which it is designed to measure
peripheral colour sensitivity changes in an arcuate man-
ner using a central fixation point. This study did not cross
examine patients with glaucoma and diabetic retinopathy
using both glaucoma and macular modules, but it is fea-
sible that further testing may reveal an overlap in colour
defect for these patients. Although the mechanism of
altered colour vision is unknown, there is evidence that
reduced retinal oxygen saturation is associated with
impaired colour vision in diabetics [15]. Error scores in
colour vision have been found to be directly correlated to
severity of macular oedema [16]. This may be similar to
the effects of retinal detachment where photoreceptors are
shifted obliquely [16]. Correlation between selective loss
of short wavelength pathway sensitivity and the severity of
diabetic macular oedema has been demonstrated [17,18].
Therefore, we have concentrated on the study of untreated
CSMO to ascertain the viability of such a screening
method. The use of smaller letters (1.5 degree; Chromat-
est module for age related macular degeneration) might
give better results for CSMO as it may test macular func-
tion better than the larger 6.5 degree optotype.
This study included only patients with type 2 diabetes to
reduce the possible variability in pathogenesis. Although
the mechanism of diabetic retinopathy is likely to be iden-
tical in both type 1 and type 2 diabetes, previous studies
such as the Early Treatment Diabetic Retinopathy Study
and Diabetic Retinopathy Study have investigated each
type of diabetes separately. Laser photocoagulation was
an exclusion criterion as it affects tritan colour vision [19].
Cataract and pseudophakia were not excluded as both are
more common in diabetics and exclusion would have
limited the usefulness of the Chromatest in screening. It is
understood that lens-yellowing effects due to cataract may
cause pre-retinal absorption of short-wavelength light
resulting in tritan deficits. This may have influenced the
overall sensitivity and specificity of the study, but it was a
representation of the realistic setting clinicians experience
in their practice.
In colour contrast testing, the higher the TCCT or PCCT
score, the more abnormal the result compared to age-
matched normal levels. 30% (35 of 115) patients with
NPDR had TCCT above normal levels. 12 male patients
were suspected to have congenital colour blindness as
their PCCT were considerably worse than normal and not
59 0.2 10.1 2.7
60 0.2 8 3.1
60 0.2 12.2 4.4
61 0 5.7 2.7
61 0 7.5 2.5
61 0.2 8.6 2.7
61 0.2 13.4 2.8
62 0 10.4 2.8
62 0.3 98.7 78.2
62 0.3 98.7 75.7
63 0 9.9 4
63 0.1 15.4 5
63 0.1 25.3 6.5
64 0 18.5 3.7
64 0.2 20.2 4
64 0.2 75.7 21.4
65 0.3 15.4 6.3
65 0.3 37.9 19.9
67 0 18.3 7.7
67 0 20.6 6.7
67 0.1 19.9 4.6
67 0.1 57.7 3.8
67 0.2 8.1 2.5
67 0.3 20 6.5
67 0.3 50.4 2.9
67 0.5 52.4 8.4
67 0.6 18.1 6.7
68 0.1 32.7 6
68 0.2 10.6 2.7
68 0.2 31.5 3.9
69 0 14.4 4.4
69 0.1 49.6 6.2
69 0.5 19.9 5.2
71 0 9.2 13.3
71 0 11.1 3.8
71 0.1 7.2 13.7
71 0.2 9.6 2.5
72 0.2 21.5 5.7
72 0.4 5.5 2.6
72 0.4 60.3 6.1
72 0.5 34.8 6.4
72 0.6 18.6 3.3
75 0 12.9 2.2
75 0.1 19.9 4
75 0.3 40.4 3.6
76 0.3 27.6 4.4
76 0.3 70.5 9.6
77 0.1 11.9 3.6
78 0 24 5.2
78 0.2 17.6 4
78 0.2 20.9 7.1
78 0.3 22.4 12.9
79 0.5 52.6 21.7
79 0.5 98.7 67.6
82 0 13.5 5.2
82 0.2 23.6 6.8
NPDR patients: Age, VA, TCCT, PCCT
Table 2: Colour Contrast Sensitivity in Patients with NPDR (N = 115) 
(Continued)BMC Ophthalmology 2008, 8:15 http://www.biomedcentral.com/1471-2415/8/15
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corresponding to their visual acuity or their fundus
appearance. This was not confirmed with any other mode
of investigation as the study was aimed at mimicking real-
istic clinical setting where high volume testing can be con-
ducted without further time consuming tests. 16 cases had
severe NPDR and may have contributed to the poor
results whereas the remaining 7 had results not corre-
sponding to their fundus appearance. We postulate that
these 7 eyes may have had concurrent disease indistin-
guishable by indirect biomicroscopy such as more
advanced ischaemia. Ultimately, fluorescein angiography
may have further elucidated the true pathology.
29% (10 of 35) CSMO patients had TCCT better than nor-
mal levels. 8 eyes had CSMO qualified as 1 disc area of ret-
inal thickening within 1 disc area of the fovea. 2 eyes had
exudates with associated retinal thickening within 500
microns of the fovea, but both were left eyes and it is pos-
sible that the patients were able to perform educated
guesses because they had been conditioned following test-
ing with their right eye.
Unfortunately, we were forced to obtain normal threshold
levels through the same dataset. These levels were
obtained through analysis of cases without CSMO. There-
fore, the results may be biased. However, because this
device is relatively new and the limited availability of fur-
ther data from diabetics, we are limited to using this data-
set to obtain "normal" threshold values. Further data will
strengthen our case of the power of this diagnostic tool.
The Chromatest is unable to successfully screen those
patients with congenital blindness and performs less well
for patients without foveal pathology. Conditioning fol-
lowing testing with the right eye may also allow patients
to perform better on their left eye. From anecdotal evi-
dence, time for testing of the second eye was observed by
the investigators to be shorter than the first eye. Repeated
testing which was not done in our study may alleviate this
problem. This study has studied more untreated CSMO
eyes with colour vision than any other that have been
published, but it requires more data to solidify our find-
ings. Colour contrast analysis may become a useful tool
for defining the need for laser treatment, but so far our
experience fails the Exeter Standards of the British Dia-
betic Association (Diabetes UK), which established
screening levels of at least 80% sensitivity and 95% specif-
icity [20].
Despite the limitations of the results, there was no dis-
crimination for age and visual acuity due to the ease of the
test. All patients were able to perform this test unlike the
1.5% of patients failing to perform another automated
TCCT test [21]. Average test time was fast at 5 minutes and
requires no mydriasis unlike fluorescein angiography and
fundus photography. Conditioning after repeated testing
is an issue for reliability, but this study was aimed at mim-
icking realistic clinical settings where patients have no
experience of colour contrast testing. Further studies to
distinguish repeatability and data for classifying normal
results from abnormals are planned. The equipment
required is relatively cheap and readily available com-
Table 3: Colour Contrast Sensitivity in Patients with CSMO (N = 
35)
Age LogMar VA Tritan Protan
31 0 8.5 3.6
31 0 11.1 4
42 0.2 14.1 4.5
44 0 7 1.9
44 0 18.8 2.6
51 0.2 8.8 2.6
52 0 29.6 3.5
52 0.3 72.3 10.7
55 0.2 18.4 3.5
56 0.3 18.4 2.9
56 0.5 36 5.6
58 0.1 7.7 2.7
58 0.3 78.2 13.7
59 0.2 23.6 3
62 0 70.5 7.7
62 0.1 49.9 11.4
63 0.4 27.3 6.7
65 0.1 85.9 14.4
65 0.3 98.7 16.9
67 0.1 16.1 3.2
67 0.2 11.8 3
67 0.3 80.8 12.4
68 0.2 13.3 3.2
69 0.1 23.3 5.3
69 0.5 30.3 16.1
70 0 21.5 6.8
70 0 35.4 5.6
70 0 32.7 5.5
70 0 62.8 9
70 0.5 98.7 20.8
71 0 98.7 14.7
71 0.2 64.8 20
71 0.3 98.7 42.3
72 0.7 68 18.4
72 0.9 57.7 16.9
CSMO patients: Age, VA, TCCT, PCCT
Table 4: χ2 test for TCCT detection of CSMO
True Positive True Negative Total
Test Positive 25 35 60
Test Negative 10 80 90
Total 35 115 150
Sensitivity = 71% (CI: 53–85%), Specificity: 70% (CI: 60–78%); χ2 test: 
p < 0.0001 comparing proportions of true positives among the test 
positive versus test negative subjectsBMC Ophthalmology 2008, 8:15 http://www.biomedcentral.com/1471-2415/8/15
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pared to those required for optical coherence tomography
or stereomacular photographs. It is also a non-invasive
procedure and less labour intensive compared to fluores-
cein angiography.
Conclusion
Non-ophthalmic doctors can have a retinopathy detection
rate of 49% compared to 96% for ophthalmologists [22].
Therefore, a cost effective method for screening is essential
for diabetic retinopathy. Screening by digital photography
proposed under the National Service Framework is
offered to all patients with diabetes in the United King-
dom. It is supplemented by biomicroscopy by the oph-
thalmologists in monitoring and treating sight
threatening disease. Furthermore, optical coherence tom-
ography has become a powerful tool in screening and
monitoring CSMO with sensitivity and specificity rates of
near 80% and 90%, respectively [23]. Perhaps with fur-
ther investigation, TCCT testing may become a supple-
ment for detecting and monitoring sight threatening
pathology without much equipment or trained techni-
cians. However, with current data, all forms of TCCT test-
ing including the Chromatest do not qualify for use in
screening for CSMO.
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